|
|
|
|
|
| Dramatic Changes of Matrix Metalloproteinases-7 and Lysozyme in the Ulcerative Colitis of Mice Induced by Dextran Sulfate Sodium |
| KANG Jing-jing, ZHAO De-ming, TENG Ke-dao, JIAO Xi-lan, WANG Ping-li, SUN Zhe, NI Peipei, WANG Zhi-feng, ZHANG Rui, YANG Yu-rong , LIANG Hong-de |
1、Pathology Laboratory, College of Animal Husbandry and Veterinary Science, Henan Agricultural University, Zhengzhou 450002, P.R.China
2、College of Animal Medicine, China Agricultural University, Beijing 100193, P.R.China |
|
|
|
摘要 Ulcerative colitis (UC) is a lifelong illness with profound emotional and social impacts, and could cause serious damage to large intestine, especially in colon. However, the pathogenesis of UC remained unclear. The present study attempts to find out the role of matrix metalloproteinases-7 (MMP-7) and lysozyme in the pathogenesis of UC through a mice model induced by dextran sulfate sodium (DSS). The UC model was evaluated both by disease activity index (DAI) and the intestinal histopathology. The results show that there is a high correlation between the DAI score and the pathological changes of colon. Interleukin-6 (IL-6) serum levels and large intestinal fluids levels in UC mice are always higher than that of the control groups, which might be associated with the degree of the inflammation damage in the colon. The change tendency of the MMP-7 mRNA and protein expressions are both up-regulated firstly and then down-regulated from 1 to 5 d in the colon, but only the MMP-7 protein is up-regulated at 7 d again. The up-regulated MMP-7 levels in the early stage of UC may play a protective role through the activated defensins, while the down-regulated levels in the mid-later stage of UC may be connected with the severe lesions in the colon. However, the up-regulated MMP-7 levels in the later stage of UC in the colon may also contribute to the tissue repair or be served as a marker to CRC (colorectal cancer). The distribution of lysozyme protein indicates that there may be Paneth-like cells in the colon. Both the changes of MMP-7 and lysozyme in the small intestine may play a protective role for the safe environment of the whole gut, especially to the colon of UC.
Abstract Ulcerative colitis (UC) is a lifelong illness with profound emotional and social impacts, and could cause serious damage to large intestine, especially in colon. However, the pathogenesis of UC remained unclear. The present study attempts to find out the role of matrix metalloproteinases-7 (MMP-7) and lysozyme in the pathogenesis of UC through a mice model induced by dextran sulfate sodium (DSS). The UC model was evaluated both by disease activity index (DAI) and the intestinal histopathology. The results show that there is a high correlation between the DAI score and the pathological changes of colon. Interleukin-6 (IL-6) serum levels and large intestinal fluids levels in UC mice are always higher than that of the control groups, which might be associated with the degree of the inflammation damage in the colon. The change tendency of the MMP-7 mRNA and protein expressions are both up-regulated firstly and then down-regulated from 1 to 5 d in the colon, but only the MMP-7 protein is up-regulated at 7 d again. The up-regulated MMP-7 levels in the early stage of UC may play a protective role through the activated defensins, while the down-regulated levels in the mid-later stage of UC may be connected with the severe lesions in the colon. However, the up-regulated MMP-7 levels in the later stage of UC in the colon may also contribute to the tissue repair or be served as a marker to CRC (colorectal cancer). The distribution of lysozyme protein indicates that there may be Paneth-like cells in the colon. Both the changes of MMP-7 and lysozyme in the small intestine may play a protective role for the safe environment of the whole gut, especially to the colon of UC.
|
|
Received: 16 October 2012
Accepted:
|
| Fund: This work was supported by the grants from the National Natural Science Foundation of China (30800812). |
|
Corresponding Authors:
YANG Yu-rong, E-mail: yangyu7712@sina.com; LIANG Hong-de, Tel: +86-371-63554600, E-mail: hdliang12@163.com
E-mail: yangyu7712@sina.com;hdliang12@163.com
|
| About author: KANG Jing-jing, E-mail: jjkang0206@gmail.com |
Cite this article:
KANG Jing-jing, ZHAO De-ming, TENG Ke-dao, JIAO Xi-lan, WANG Ping-li, SUN Zhe, NI Peipei, WANG Zhi-feng, ZHANG Rui, YANG Yu-rong , LIANG Hong-de.
2014.
Dramatic Changes of Matrix Metalloproteinases-7 and Lysozyme in the Ulcerative Colitis of Mice Induced by Dextran Sulfate Sodium. Journal of Integrative Agriculture, 13(4): 858-859.
|
| Adachi Y, Yamamoto H, Itoh F, Hinoda Y, Okada Y, Imai K. 1999. Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers Gut, 45, 252-258. Asakura H. 1998. Ulcerative colitis and intestinal bleeding. Nihon Rinsho, 56, 2354-2359. Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, Schütz M, Bartsch B, Holtmann M, Becker C, et al. 2000. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nature Medicine, 6, 583- 588. Baugh M D, Perry M J, Hollander A P, Davies D R, Cross S S, Lobo A J, Taylor C J, Evans G S. 1999. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology, 117, 814-822 Brown K A, Back S J, Ruchelli E D, Markowitz J, Mascarenhas M, Verma R, Piccoli D A, Baldassano R N. 2002. Lamina propria and circulating interleukin-6 in newly diagnosed pediatric inflammatory bowel disease patients The American Journal of Gastroenterology, 97, 2603-2608 Cooper H S, Murthy S N, Shah R S, Sedergran D J. 1993. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Laboratory Investigation, 69, 238-249 Crohn B B, Rosenberg H. 1925. The sigmoidoscopic picture of chronic ulcerative colitis (non-specific). Americn Journal of Medical Sciences, 170, 220-227 Eaden J A, Abrams K R, Mayberry J F. 2001. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut, 48, 526-535 Fahlgren A, Hammarström S, Danielsson A, Hammarström M L. 2003. Increased expression of antimicrobial peptides and lysozyme in colonic epithelial cells of patients with ulcerative colitis. Clinical and Experimental Immunology, 131, 90-101 Grosse Hülsewiesche A, Grosse G, Kevenoglu M, Niedobitek F, Volkheimer G. 1989. Lysozyme and lactoferrin in normal and inflammatory changes of the gastric mucosa. Zeitschriftfur Gastroenterology, 27, 714- 721. Heuschkel R B, MacDonald T T, Monteleone G, Bajaj- Elliott M, Smith J A, Pender S L. 2000. Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease Gut, 47, 57- 62. Holtkamp W, Stollberg T, Reis H E. 1995. Serum interleukin-6 is related to disease activity but not disease specificity in inflammatory bowel disease Journal of Clinical Gastroenterology, 20, 123-126 Hyams J S, Fitzgerald J E, Treem W R, Wyzga N, Kreutzer D L. 1993. Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease. Gastroenterology, 104, 1285-1292 Klockars M, Reitamo S. 1975. Tissue distribution of lysozyme in man. The Journal of Histochemistry and Cytochemistry, 23, 932-940 von Lampe B, Barthel B, Coupland S E, Riecken E O, Rosewicz S. 2000. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut, 47, 63-73 Louis E, Belaiche J, van Kemseke C, Franchimont D, de Groote D, Gueenen V, Mary J Y. 1997. A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn’s disease European Journal of Gastroenterology & Hepatology, 9, 939-944 Mitsuyama K, Sata M, Rose-John S. 2006. Interleukin-6 trans-signaling in inflammatory bowel disease Cytokine & Growth Factor Reviews, 17, 451-461 Miyazaki K, Hattori Y, Umenishi F, Yasumitsu H, Umeda M. 1990. Purification and characterization of extracellular matrix-degrading metalloproteinase, matrin (pump-1), secreted from human rectal carcinoma cell line Cancer Research, 50, 7758-7764. Montero C, Erlandsen S L. 1978. Immunocytochemical and histochemical studies on intestinal epithelial cells producing both lysozyme and mucosubstance. The Anatomical Record, 190, 127-141 Mudter J, Neurath M F. 2007. Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications. Gut, 56, 293-303 Mudter J, Neurath M F. 2007. IL-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance Inflammatory Bowel Diseases, 13, 1016-1023. Neurath M F, Finotto S. 2009. Translating inflammatory bowel disease research into clinical medicine. Immunity, 31, 357-361 Newell K J, Witty J P, Rodgers W H, Matrisian L M. 1994. Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis. Molecular Carcinogenesis, 10, 199-206 Owczarek D, Cibor D, Szczepanek M, Mach T. 2009. Biological therapy of inflammatory bowel disease. Polskie Archiwum Medycyny Wewnetrznej, 119, 84-88 Reinisch W, Gasché C, Tillinger W, Wyatt J, Lichtenberger C, Willheim M, Dejaco C, Waldhör T, Bakos S, Vogelsang H, et al. 1999. Clinical relevance of serum interleukin-6 in Crohn’s disease: single point measurements, therapy monitoring, and prediction of clinical relapse The American Journal of Gastroenterology, 94, 2156-2164. Saarialho-Kere U K, Vaalamo M, Puolakkainen P, Airola K, Parks W C, Karjalainen-Lindsberg M L. 1996. Enhanced expression of matrilysin, collagenase, and stromelysin-1 in gastrointestinal ulcers The American Journal of Pathology, 148, 519-526. Sava G, Bergamo A, Capozzi I, Clerici K, Pacor S, Gagliardi R, Giacomello E, Zacchigna M, di Luca G, Boccu E. 1996. Stimulation of GALT and activation of mesenteric lymph node lymphocytes by a modified lysozyme in CBA mice with MCa mammary carcinoma. Journal of Experimental Therapeutics & Oncology, 1, 342-349 Shanahan F, Bernstein C N. 2009. The evolving epidemiology of inflammatory bowel disease. Current Opinion in Gastroenterology, 25, 301-305 Stallmach A, Chan C C, Ecker KW, Feifel G, Herbst H, Schuppan D, Zeitz M. 2000. Comparable expression of matrix metalloproteinases 1 and 2 in pouchitis and ulcerative colitis. Gut, 47, 415-422 Umehara Y, Kudo M, Nakaoka R, Kawasaki T, Shiomi M. 2006. Serum proinflammatory cytokines and adhesion molecules in ulcerative colitis. Hepato-Gastroenterology, 53, 879-882 Vaalamo M, Karjalainen-Lindsberg M L, Puolakkainen P, Kere J, Saarialho-Kere U. 1998. Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP- 3) in intestinal ulcerations The American Journal of Pathology, 152, 1005-1014. Wilson C L, Matrisian L M. 1996. Matrilysin: An epithelial matrix metalloproteinase with potentially novel functions. The International Journal of Biochemistry & Cell Biology, 28, 123-136 Wilson C L, Matrisian L M. 1998. Matrilysin. In: Parks W C, Mecham R P, eds., Matrix Metalloproteinases. Academic Press, New York. pp. 149-184 Wilson C L, Ouellette A J, Satchell D P, Ayabe T, López- Boado Y S, Stratman J L, Hultgren S J, Matrisian L M, Parks W C. 1999. Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Science, 286, 113-117 Woessner Jr J F, Taplin C J. 1988. Purification and properties of a small latent matrix metalloproteinase of the rat uterus. The Journal of Biological Chemistry, 263, 16918-16925 Yamamoto H, Itoh F, Adachi Y, Iku S, Fukushima H, Horiuchi S, Min Y, Sasaki S, Imai K. 2000. Matrix metalloproteinase matrilysin in cancers of the digestive organs. Tumor Research, 35, 1-12 |
| No Suggested Reading articles found! |
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
